Kathleen Hanrahan

Kathleen Hanrahan

Auto-generated profile, based on publicly available information

Kathleen Hanrahan

Department of Pharmacy Arnot Ogden Medical Center Elmira New York USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2024 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
WKWesley Kufel
Wesley Kufel
KHKathleen D Hanrahan
Kathleen D Hanrahan
RSRobert W Seabury
Robert W Seabury
KPKatie A Parsels
Katie A Parsels
JGJason C Gallagher
Jason C Gallagher
JSJeffrey M Steele
Jeffrey M Steele
Background: It is unknown whether ChatGPT provides quality responses to infectious diseases (ID) pharmacotherapy questions. This study surveyed ID pharmacist subject matter experts (SMEs) to assess the quality of ChatGPT version 3.5 (GPT-3.5) responses. Methods: The primary outcome was the percentage of GPT-3.5 responses considered useful by SME rating. Secondary outcomes were SMEs' ratings of correctness, completeness, and safety. Rating definitions were based on literature review. One hundred ID pharmacotherapy questions were entered into GPT-3.5 without custom instructions or additional prompts, and responses were recorded. A 0–10 rating scale for correctness, completeness, and safety was developed and validated for interrater reliability. Continuous and categorical variables were assessed for interrater reliability via average measures intraclass correlation coefficient and Fleiss multirater kappa, respectively. SMEs' responses were compared by the Kruskal-Wallis test and chi-square test for continuous and categorical variables. Results: SMEs considered 41.8% of responses useful. Median (IQR) ratings for correctness, completeness, and safety were 7 (4–9), 5 (3–8), and 8 (4–10), respectively. The Fleiss multirater kappa for usefulness was 0.379 (95% CI, .317–.441) indicating fair agreement, and intraclass correlation coefficients were 0.820 (95% CI, .758–.870), 0.745 (95% CI, .656–.816), and 0.833 (95% CI, .775–.880) for correctness, completeness, and safety, indicating at least substantial agreement. No significant difference was observed among SME responses for percentage of responses considered useful. Conclusions: Fewer than 50% of GPT-3.5 responses were considered useful by SMEs. Responses were mostly considered correct and safe but were often incomplete, suggesting that GPT-3.5 responses may not replace an ID pharmacist's responses.

15 May 2025 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Open access
WKWesley Kufel
Wesley Kufel
NZNabil Zeineddine
Nabil Zeineddine
AFAliaa Fouad
Aliaa Fouad
HRHanna F. Roenfanz
Hanna F. Roenfanz
RSRyan Shields
Ryan Shields
JKJoseph L Kuti
Joseph L Kuti
Background: Drug databases currently do not provide dosing guidance for sulbactam‐durlobactam in continuous renal replacement therapy. Herein, we present the first in vivo pharmacokinetic (PK) evaluation of sulbactam‐durlobactam during continuous venovenous hemofiltration (CVVH) in a patient with carbapenem‐resistant Acinetobacter baumannii‐calcoaceticus complex (CRAB) bacteremia and ventilator‐associated bacterial pneumonia (VABP). Methods: A 59‐year‐old critically ill patient (body mass index 60 kg/m 2 ) required CVVH and developed CRAB bacteremia secondary to VABP. Sulbactam‐durlobactam 2 g every 4 h infused over 3 h was initiated based on previous ex vivo data and the effluent rate of 6 L/h. The sulbactam‐durlobactam minimum inhibitory concentration (MIC) was determined by reference broth microdilution, and whole genome sequencing (WGS) was performed. Steady‐state pre‐filter blood, post‐filter blood, and effluent samples were collected on three different dosing intervals to characterize plasma exposure and estimate the sieving coefficient (SC). Results: The sulbactam‐durlobactam MIC was 4/4 mcg/mL (susceptible). WGS revealed penicillin‐binding protein (PBP)‐1b and PBP‐3 mutations. The selected dose exceeded sulbactam and durlobactam PK/pharmacodynamic (PD) targets with 100% free time above MIC ( f T > MIC) and the ratio of area under the unbound concentration‐time curve to MIC ( f AUC/MIC) = 139, respectively. The SC for sulbactam and durlobactam was 0.68 and 0.67, respectively, and protein binding was 54% and 51%, respectively. Sulbactam‐durlobactam monotherapy resulted in initial microbiological clearance for CRAB bacteremia but recurred later in hospitalization 11 days after sulbactam‐durlobactam treatment. The patient was ultimately transitioned to comfort care. Conclusion: Sulbactam‐durlobactam monotherapy dosed at 2 g every 4 h (3‐h infusion) in CVVH achieved PD targets for this CRAB isolate with a MIC of 4/4 mcg/ml. Although sulbactam‐durlobactam monotherapy resulted in initial microbiological clearance for the CRAB bacteremia, recurrence occurred, and the patient ultimately died.